Table 6.
Changes in serum metabolic variables during the course of the study
| Factor | Probability | Regression | ||
|---|---|---|---|---|
| Total cholesterol (mg/dL) | Whole model | Group | p=0.063 | CP1563: δT-C=30.0878−0.132×Init. T-C |
| Group×Init. T-C | p<0.001 | Placebo: δT-C=14.012−0.068×Init. T-C | ||
| Female | Group | p=0.884 | CP1563: δT-C=19.889−0.084×Init. T-C | |
| Group×Init. T-C | p=0.006 | Placebo: δT-C=18.237−0.079×Init. T-C | ||
| Male | Group | p=0.029 | CP1563: δT-C=43.043−0.192×Init. T-C | |
| Group×Init. T-C | p<0.001 | Placebo: δT-C=13.360−0.073×Init. T-C | ||
| HDL-cholesterol (mg/dL) | Whole model | Group | p=0.574 | CP1563: δHDL-C=3.462−0.054×Init. HDL-C |
| Group×Init. HDL-C | p=0.004 | Placebo: δHDL-C=2.498−0.042×Init. HDL-C | ||
| Female | Group | p=0.631 | CP1563: δHDL-C=3.527−0.055×Init. HDL-C | |
| Group×Init. HDL-C | p=0.244 | Placebo: δHDL-C=2.016−0.016×Init. HDL-C | ||
| Male | Group | p=0.413 | CP1563: δHDL-C=3.439−0.054×Init. HDL-C | |
| Group×Init. HDL-C | p<0.001 | Placebo: δHDL-C=5.118−0.112×Init. HDL-C | ||
| LDL-cholesterol (mg/dL) | Whole model | Group | p=0.014 | CP1563: δLDL-C=23.956−0.170×Init. LDL-C |
| Group×Init. LDL-C | p<0.001 | Placebo: δLDL-C=10.863−0.083×Init. LDL-C | ||
| Female | Group | p=0.299 | CP1563: δLDL-C=19.785−0.141×Init. LDL-C | |
| Group×Init. LDL-C | p<0.001 | Placebo: δLDL-C=12.117−0.089×Init. LDL-C | ||
| Male | Group | p=0.019 | CP1563: δLDL-C=28.728−0.202×Init. LDL-C | |
| Group×Init. LDL-C | p<0.001 | Placebo: δLDL-C=8.559−0.080×Init. LDL-C | ||
| Triglyceride (mg/dL) | Whole model | Group | p=0.950 | CP1563: δTG=21.142−0.176×Init. TG |
| Group×Init. TG | p<0.001 | Placebo: δTG=20.767−0.168×Init. TG | ||
| Female | Group | p=0.216 | CP1563: δTG=37.363−0.144×Init. TG | |
| Group×Init. TG | p<0.001 | Placebo: δTG=27.526−0.267×Init. TG | ||
| Male | Group | p=0.604 | CP1563: δTG=23.7438−0.194×Init. TG | |
| Group×Init. TG | p<0.001 | Placebo: δTG=18.927−0.118×Init. TG | ||
| Fasting glucose (mg/dL) | Whole model | Group | p<0.001 | CP1563: δGLC=15.101−0.161×Init. GLC |
| Group×Init. GLC | p<0.001 | Placebo: δGLC=−5.624+0.071×Init. GLC | ||
| Female | Group | p=0.001 | CP1563: δGLC=23.229−0.250×Init. GLC | |
| Group×Init. GLC | p<0.001 | Placebo: δGLC=6.949−0.086×Init. GLC | ||
| Male | Group | p=0.004 | CP1563: δGLC=2.886−0.024×Init. GLC | |
| Group×Init. GLC | p<0.001 | Placebo: δGLC=−13.855+0.179×Init. GLC | ||
| Fasting insulin (mU/mL) | Whole model | Group | p=0.418 | Incomputable |
| Group×Init. Ins. | p=0.004 | |||
| HOMA-IR | Whole model | Group | p=0.598 | Incomputable |
| Group×Init. HOMA-IR | p<0.001 | |||
| Uric acid (mg/dL) | Whole model | Group | p=0.022 | CP1563: δUA=0.822−0.144×Init. UA |
| Group×Init. UA | p<0.001 | Placebo: δUA=0.436+0.087×Init. UA | ||
| Female | Group | p=0.029 | CP1563: δUA=0.603−0.104×Init. UA | |
| Group×Init. UA | p=0.005 | Placebo: δUA=0.067+0.020×Init. UA | ||
| Male | Group | p=0.870 | CP1563: δUA=1.070−0.180×Init. UA | |
| Group×Init. UA | p<0.001 | Placebo: δUA=1.019+0.169×Init. UA |
T-C, total cholesterol; Init., initial; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; TG, triglyceride; GLC, glucose; Ins, insulin; HOMA-IR, homeostasis model assessment-insulin resistance; UA, uric acid.
Statistical analysis with ANCOVA was used for repeated measures, except for the items ‘fasting insulin’ and ‘HOMA-IR’.
The fasting insulin concentration was measured at only 2 time points: before and after ingestion; therefore, ANCOVA was used for these variables.